Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion for fatigue and quality of life in multiple sclerosis
IRCT20190325043107N48Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Bupropion plus routine treatment with Placebo plus routine treatment (2 arms). Primary endpoint: Quality of life. Started Oct 2024; status: completed.
02
Drugs
bupropion
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20190325043107N48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190325043107N48.